We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Vantia Therapeutics raises $6.5 million

Vantia Therapeutics raises $6.5 million

July 6, 2011
CenterWatch Staff

Pharmaceutical company Vantia Therapeutics has raised $6.5 million in a series B round. The round was co-led by Novo and SV Life Sciences, and included MVM Life Science Partners.

The funding will advance development of Vantia's two clinical candidates, VA106483 for nocturia and VA111913 for dysmenorrhoea, both of which are in phase II trials.

An exploratory phase II trial of VA111913 in the treatment of dysmenorrhoea (painful periods) showed promising evidence of reduced pain levels in patients. VA111913 was well tolerated and significant differences between VA111913 treatment and placebo were seen for a number of efficacy endpoints. The study identified a target population that derived a substantial reduction in period pain fromVA111913 treatment.

VA106483 is being investigated as a new treatment for nocturia in a 30-patient clinical trial to evaluate the dose-response in men aged over 65 years with benign prostatic hypertrophy (BPH). The results are expected in the second half of 2011. Data from previous trials demonstrated a dose-dependent pharmacological effect and suggested VA106483 has potential to be an effective and well-tolerated antidiuretic for the treatment of nocturia.

Global News Awards & Advancement

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing